Moderna, Inc. announced the appointment of Juan Andres as Chief Operating Officer (COO), effective October 5, 2026. The newly created role is intended to support the company's increasing scale and diversification. Mr. Andres will report to Chief Executive Officer Stéphane Bancel and serve on the Company’s Executive Committee.
Mr. Andres, 62, previously spent nearly six years at Moderna. He served as Chief Technical Operations and Quality Officer from 2018 through 2022 and as President, Strategic Partnerships and Enterprise Expansion before retiring from the company in 2023. During his prior tenure, he led the build-out and scale-up of Moderna’s manufacturing capabilities, including the rapid expansion of the global manufacturing network to support the COVID-19 vaccine.
In connection with his employment, Mr. Andres will receive an initial annual base salary of $800,000. He is eligible for an annual cash bonus with a target of 90% of his base salary. Additionally, he will receive a new hire equity award valued at $5,000,000, subject to a four-year vesting period. The equity grant may be delivered as a mix of non-qualified stock options and restricted stock units (RSUs), with no more than 75% of the value delivered as RSUs.
Moderna also announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire from the company. Dr. Collins joined Moderna in October 2022 and became Chief Technical Operations and Quality Officer in January 2023. During his tenure, he helped transition the manufacturing footprint for an endemic vaccine market and established the manufacturing model to support intismeran autogene.
Moderna noted that the infectious disease franchise now includes five approved vaccines following the recent U.S. FDA approval of the seasonal flu vaccine and the European Commission marketing authorization of the seasonal flu plus COVID combination vaccine.
